FDA to encourage new manufacturing sites with its PreCheck programme
The scheme will provide more support and a streamlined application process to companies constructing new US facilities.
List view / Grid view
News
Steady progress for UK healthcare M&A in H1, report finds
Amid shifting global dynamics, continued resilience in UK healthcare M&A deal activity is expected in H2 2025, forecasting predicts.
EU Biotech Act public consultation opens for input
The European Commission hopes its planned legislation will enable biotechnology companies to bring products from laboratory to market more quickly.
AI driving automated microbiological testing market growth to 2033
Regulatory pressures and demand for trained operators is expected to hinder growth of the rapid microbiological testing market into the next decade, research suggests.
mRNA vaccine research worth $500m cut by RFK Jr
HHS throws out Pfizer, CSL Seqirus and Sanofi proposals, and will restructure AstraZeneca and Moderna projects.
Biowaste innovation could advance green pharmaceutical production
The novel approach could reduce the industry’s reliance on fossil fuels by offering a sustainable production alternative for pharmaceuticals.
Sanofi accelerates towards its ‘factory of the future’ vision
New digital initiative will support the pharma company’s manufacturing and supply chain ambitions.
New AbbVie data highlights Rinvoq promise in alopecia areata
The trial is the first pivotal clinical programme to have met the standard of complete scalp hair regrowth, suggesting potential in immune-mediated diseases.
Ofichem acquires Uppsala site from Meribel Pharma Solutions
The deal between the two European CDMOs expands Ofichem’s Nordic biotech footprint and drug substance capabilities.
Sandoz acquisition to boost in-house biosimilar capabilities
The proposed transaction means Just-Evotec Biologics’ Toulouse site would be used to develop and manufacture Sandoz biosimilars.
Broad label FDA approval for phenylketonuria drug
Alongside Phase III data demonstrating significant efficacy in the rare disease, the FDA’s decision could position the small molecule as a future standard of care.
Extension trial demonstrates long-term benefit for Lilly Alzheimer’s drug
The new findings support a limited duration dosing approach and highlight the consistent safety profile for Eli Lilly’s antibody drug.
EU and US agree preliminary tariffs deal
Marking the first step in the negotiation process, this deal establishes key parameters of the final political agreement on trade and tariffs between the EU and US.
Bristol Myers Squibb names new Head of Development
The new appointee has over twenty years of experience in biopharma and extensive senior expertise in oncology.
Considerations for contact plate recovery in cleanrooms
The study provides greater insight into some of the key factors that affect microbiological surface contamination in cleanrooms.
